Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022137133 - RNA VACCINE AGAINST SARS-COV-2 VARIANTS

Publication Number WO/2022/137133
Publication Date 30.06.2022
International Application No. PCT/IB2021/062127
International Filing Date 21.12.2021
IPC
A61K 39/12 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61K 39/215 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
A61P 11/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
CPC
A61K 2039/53
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
53DNA (RNA) vaccination
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
A61P 11/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C12N 2770/20011
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2770ssRNA Viruses positive-sense
00011ssRNA Viruses positive-sense
20011Coronaviridae
Applicants
  • CUREVAC AG [DE]/[DE]
  • GLAXOSMITHKLINE BIOLOGICALS SA [BE]/[BE]
Inventors
  • ROTH, Nicole
  • MORENO, Diego Chaves
  • GROßE, Hans Wolfgang
  • VAHRENHORST, Dominik
  • RAUCH, Susanne
Priority Data
63/129,39522.12.2020US
PCT/EP2021/05245503.02.2021EP
PCT/EP2021/06962614.07.2021EP
PCT/EP2021/06963214.07.2021EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) RNA VACCINE AGAINST SARS-COV-2 VARIANTS
(FR) VACCIN À ARN CONTRE DES VARIANTS SRAS-COV-2
Abstract
(EN) The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID- 19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
(FR) La présente invention concerne un acide nucléique approprié pour une utilisation dans le traitement ou la prophylaxie d'une infection à coronavirus, de préférence à coronavirus SARS-CoV-2, ou d'un trouble associé à cette infection, de préférence la COVID-19. La présente invention concerne également des compositions, des polypeptides et des vaccins. Les compositions et les vaccins comprennent de préférence au moins l'une desdites séquences d'acides nucléiques, de préférence des séquences d'acides nucléiques en association avec une nanoparticule lipidique (LNP). L'invention concerne également des première et seconde utilisations médicales de l'acide nucléique, de la composition, du polypeptide, de la combinaison, du vaccin et du kit, et des méthodes de traitement ou de prévention d'une infection à coronavirus, de préférence d'une infection à coronavirus.
Latest bibliographic data on file with the International Bureau